TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2145377

Group type: EXPERIMENTAL
Intervention: Human plasminogen
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Human plasmin
Number of subjects: 500

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: E. coli endotoxin or oleic acid (in experimental animals)
Number of subjects: 500
Study: 734578

Group type: EXPERIMENTAL
Intervention: Segmental epidural block with lower dosages of bupivacaine; specific dosage not mentioned; technique involved patients kneeling on all fours.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard and modified segmental epidural block; specific dosages and techniques not mentioned.
Number of subjects: 0
Study: 30676045

Group type: EXPERIMENTAL
Intervention: Brief Warrior Renew treatment (8 sessions)
Number of subjects: 39
Study: 31564281

Group type: EXPERIMENTAL
Intervention: Valsartan combined with Alpha-lipoic Acid (ALA)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Valsartan alone
Number of subjects: 102
Study: 27193583

Group type: EXPERIMENTAL
Intervention: PUFA-rich diet
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 26
Study: 25638038

Group type: EXPERIMENTAL
Intervention: Tailored, personalized site (treatment)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Test-locator condition (control)
Number of subjects: 130
Study: 24099353

Group type: EXPERIMENTAL
Intervention: Positive cue context (listening to vignettes describing positive drinking scenarios)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Negative cue context (listening to vignettes describing negative drinking scenarios)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Less problematic drinkers in either cue condition
Number of subjects: 0
Study: 21415073

Group type: EXPERIMENTAL
Intervention: Off-pump CABG
Number of subjects: 341

Group type: COMPARATOR
Intervention: On-pump CABG
Number of subjects: 341
Study: 19357698

Group type: EXPERIMENTAL
Intervention: Telmisartan 80 mg and HCTZ 25 mg
Number of subjects: 2121

Group type: EXPERIMENTAL
Intervention: Valsartan 160 mg and HCTZ 25 mg
Number of subjects: 2121

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2121

Group type: EXPERIMENTAL
Intervention: Telmisartan-HCTZ
Number of subjects: 2121

Group type: EXPERIMENTAL
Intervention: Valsartan-HCTZ
Number of subjects: 2121
Study: 17961200

Group type: EXPERIMENTAL
Intervention: Needs-based cognitive-behavioural family intervention
Number of subjects: 60

Group type: COMPARATOR
Intervention: Routine care (Control)
Number of subjects: 60
Study: 15136065

Group type: EXPERIMENTAL
Intervention: Higher levels of circulating oxidized low-density lipoprotein (oxLDL)
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Highest quartile of oxLDL levels
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Third quartile of oxLDL levels
Number of subjects: 238
Study: 11340684

Group type: EXPERIMENTAL
Intervention: Inhaled recombinant human DNase (rhDNase)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 9263304

Group type: EXPERIMENTAL
Intervention: Classroom-based skin cancer prevention lesson
Number of subjects: 0

Group type: COMPARATOR
Intervention: Interactive sun safety fair
Number of subjects: 0
Study: 8243793

Group type: EXPERIMENTAL
Intervention: Salbutamol (200 micrograms)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Salmeterol (50 micrograms)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 3517534

Group type: EXPERIMENTAL
Intervention: Middle ear irrigation
Number of subjects: 220

Group type: COMPARATOR
Intervention: Control group (no irrigation)
Number of subjects: 220
Study: 30154254

Group type: EXPERIMENTAL
Intervention: Stent retriever (SR) treatment with SVS present
Number of subjects: 217

Group type: COMPARATOR
Intervention: Stent retriever (SR) treatment without SVS
Number of subjects: 217
Study: 28646900

Group type: EXPERIMENTAL
Intervention: HUMSC-CM
Number of subjects: 68
Study: 25555361

Group type: EXPERIMENTAL
Intervention: Wii Balance Board (WBB)
Number of subjects: 35
Study: 23925452

Group type: EXPERIMENTAL
Intervention: Modafinil (up to 400 mg/day)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 21830049

Group type: EXPERIMENTAL
Intervention: Titration of sevoflurane based on SEDLine™ data
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual clinical criteria (control group)
Number of subjects: 0
Study: 19685411

Group type: EXPERIMENTAL
Intervention: Diet associated with exercise training (DET)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Diet alone (D)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (lean children)
Number of subjects: 38
Study: 17910221

Group type: EXPERIMENTAL
Intervention: Futura Bond NR (self-etching adhesive)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (without application of a desensitizing agent)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Fluor Protector (desensitizing treatment)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: VivaSens (desensitizing treatment)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Isodan (desensitizing treatment)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Futura Bond NR (desensitizing treatment)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Nd:YAG laser (desensitizing treatment)
Number of subjects: 24
Study: 15133865

Group type: EXPERIMENTAL
Intervention: Bifid triple viable capsule (BIFICO) (1.26 g/d)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (starch)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: BIFICO
Number of subjects: 30
Study: 11134427

Group type: EXPERIMENTAL
Intervention: Early diagnosis through neonatal screening
Number of subjects: 650341

Group type: COMPARATOR
Intervention: Standard diagnosis (control group)
Number of subjects: 650341
Study: 9232049

Group type: EXPERIMENTAL
Intervention: Discharge package containing a manual breast pump only
Number of subjects: 763

Group type: EXPERIMENTAL
Intervention: Discharge package containing a commercially prepared infant formula and a manual breast pump
Number of subjects: 763

Group type: COMPARATOR
Intervention: Commercially prepared infant formula discharge package only (Control)
Number of subjects: 763

Group type: EXPERIMENTAL
Intervention: Providing formula samples at discharge from the hospital
Number of subjects: 763
Study: 8333941

Group type: EXPERIMENTAL
Intervention: 1% fusidic acid viscous eye drops, self-administered four times daily for seven days before surgery
Number of subjects: 79

Group type: COMPARATOR
Intervention: Placebo (inert ophthalmic drops)
Number of subjects: 79
Study: 3080285

Group type: EXPERIMENTAL
Intervention: misoprostol (200 micrograms four times daily) with tolmetin (2000 mg/day, in four divided doses)
Number of subjects: 60

Group type: COMPARATOR
Intervention: placebo with tolmetin (2000 mg/day, in four divided doses)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: misoprostol with tolmetin
Number of subjects: 60
Study: 2790669

Group type: EXPERIMENTAL
Intervention: Lorazepam
Number of subjects: 100

Group type: COMPARATOR
Intervention: Oxazepam
Number of subjects: 100

Group type: COMPARATOR
Intervention: Methylprednisolone
Number of subjects: 100
Study: 30823563

Group type: EXPERIMENTAL
Intervention: Animal-source food (ASF) consumption
Number of subjects: 355
Study: 27862291

Group type: EXPERIMENTAL
Intervention: Probe-based confocal laser endomicroscopy (pCLE)
Number of subjects: 101

Group type: COMPARATOR
Intervention: White-light imaging with chromoendoscopy (CE)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Both pCLE and CE
Number of subjects: 101
Study: 26440754

Group type: EXPERIMENTAL
Intervention: Action Planning (AP) intervention
Number of subjects: 1982

Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 1982
Study: 24206547

Group type: EXPERIMENTAL
Intervention: Intermittent Boluses (IB) - 20 mg propofol boluses on demand
Number of subjects: 192

Group type: COMPARATOR
Intervention: Pump Continuous Infusion (PCI) - 3 mg/kg/h plus 20 mg boluses on demand
Number of subjects: 192
Study: 22040007

Group type: EXPERIMENTAL
Intervention: 6-month lifestyle intervention consisting of individual counseling using motivational interviewing techniques
Number of subjects: 816

Group type: COMPARATOR
Intervention: usual care
Number of subjects: 816
Study: 19593179

Group type: EXPERIMENTAL
Intervention: Chamomile extract therapy
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 61
Study: 17229901

Group type: EXPERIMENTAL
Intervention: Soy protein (40 g soy protein, 118 mg isoflavones)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Soy protein
Number of subjects: 41

Group type: COMPARATOR
Intervention: Gluten placebo
Number of subjects: 41
Study: 12774015

Group type: EXPERIMENTAL
Intervention: Amantadine group (amantadine sulphate 100 mg twice daily orally)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Control group (IFN-alpha plus ribavirin)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Amantadine group
Number of subjects: 400

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Amantadine group (HCV genotype 1)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Control group (HCV genotype 1)
Number of subjects: 400
Study: 10703678

Group type: EXPERIMENTAL
Intervention: Vitamin E (1200 IU of all‐rac‐alpha‐tocopheryl acetate taken 6 h before hemodialysis)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control (without vitamin E supplementation)
Number of subjects: 22
Study: 9216458

Group type: EXPERIMENTAL
Intervention: Daily smokers
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Weekly alcohol consumption
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Gender
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Reference interval for P‐MDA
Number of subjects: 213
Study: 8267669

Group type: EXPERIMENTAL
Intervention: Oxerutins (900 mg/day for 12 weeks)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Troxerutin (900 mg/day for 12 weeks)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Oxerutins
Number of subjects: 12
Study: 3710631

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Molsidomine
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 29569219

Group type: EXPERIMENTAL
Intervention: Cabergoline (D2-receptor agonist)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 26683763

Group type: EXPERIMENTAL
Intervention: Daclatasvir (DCV) plus asunaprevir (ASV)
Number of subjects: 229
Study: 24491193

Group type: EXPERIMENTAL
Intervention: Premonitory Urge to Tic Scale (PUTS)
Number of subjects: 122
Study: 23840645

Group type: EXPERIMENTAL
Intervention: Wake therapy (sleep deprivation) combined with light therapy and sleep time stabilisation
Number of subjects: 74

Group type: COMPARATOR
Intervention: Exercise
Number of subjects: 74
Study: 20617906

Group type: EXPERIMENTAL
Intervention: Ultrasound gel
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 1-cm-thick pad
Number of subjects: 48

Group type: COMPARATOR
Intervention: 2-cm-thick pad
Number of subjects: 48
Study: 18261193

Group type: EXPERIMENTAL
Intervention: Multi-component alcohol use preventive intervention
Number of subjects: 5812

Group type: EXPERIMENTAL
Intervention: Home-based programs
Number of subjects: 5812

Group type: COMPARATOR
Intervention: Control condition ('prevention as usual')
Number of subjects: 5812

Group type: EXPERIMENTAL
Intervention: Intervention communities
Number of subjects: 5812
Study: 15722280

Group type: EXPERIMENTAL
Intervention: Dynamic ultrasound
Number of subjects: 33

Group type: COMPARATOR
Intervention: Stress radiography
Number of subjects: 33
Study: 11943634

Group type: EXPERIMENTAL
Intervention: Iodized salt
Number of subjects: 400
Study: 9638026

Group type: EXPERIMENTAL
Intervention: Uphill running
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Downhill running
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Ultramarathon (67 km distance; 30 km downhill running)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Alpine long-distance cycling (230 km distance)
Number of subjects: 53
Study: 7648158

Group type: EXPERIMENTAL
Intervention: Polyglyconate sutures
Number of subjects: 204

Group type: COMPARATOR
Intervention: Polyglycolic acid sutures
Number of subjects: 204
Study: 2554630

Group type: EXPERIMENTAL
Intervention: Desferrioxamine B 500 mg intravenously followed by packed red cell transfusion
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (only transfused)
Number of subjects: 24
Study: 782774

Group type: EXPERIMENTAL
Intervention: Butorphanol 1 mg/70 kg
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Butorphanol 2 mg/70 kg
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Butorphanol 4 mg/70 kg
Number of subjects: 104

Group type: COMPARATOR
Intervention: Meperidine 40 mg/70 kg
Number of subjects: 104

Group type: COMPARATOR
Intervention: Meperidine 80 mg/70 kg
Number of subjects: 104
Study: 30415628

Group type: EXPERIMENTAL
Intervention: Icosapent ethyl (2 g twice daily, total daily dose 4 g)
Number of subjects: 8179

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8179
Study: 29925712

Group type: EXPERIMENTAL
Intervention: 1% malic acid spray
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 70
Study: 26572686

Group type: EXPERIMENTAL
Intervention: Faldaprevir 240 mg once daily plus PegIFN/RBV for 24 weeks
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Faldaprevir
Number of subjects: 118
Study: 24924261

Group type: EXPERIMENTAL
Intervention: UFT/LV plus irinotecan (n = 23)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: UFT/LV plus oxaliplatin (n = 28)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: TP53 mutation status
Number of subjects: 51
Study: 22229837

Group type: EXPERIMENTAL
Intervention: Transdermal sumatriptan
Number of subjects: 530
Study: 19297310

Group type: EXPERIMENTAL
Intervention: ICD-9 diagnoses with somatization potential
Number of subjects: 1364

Group type: EXPERIMENTAL
Intervention: Clinician-rated somatization
Number of subjects: 1364
Study: 17848678

Group type: EXPERIMENTAL
Intervention: CT findings for in situ carcinoma
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: CT findings for invasive carcinoma
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: CT for determining resectability
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: CT for determining unresectability
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Overall accuracy of CT
Number of subjects: 46
Study: 14722645

Group type: EXPERIMENTAL
Intervention: 0.28 g of glutamine per kg bodyweight per day intravenously for five days
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 0.57 g of glutamine per kg bodyweight per day intravenously for five days
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 0.86 g of glutamine per kg bodyweight per day intravenously for five days
Number of subjects: 40

Group type: COMPARATOR
Intervention: 0 g of glutamine per kg bodyweight per day intravenously for five days (control)
Number of subjects: 40
Study: 12201937

Group type: EXPERIMENTAL
Intervention: ESWL with diuresis (i.v. infusion of 500 ml normal saline containing 40 mg furosemide)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Standard ESWL
Number of subjects: 106
Study: 9653697

Group type: EXPERIMENTAL
Intervention: Single dose of azithromycin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard course of erythromycin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard course of tetracycline (for sexual partners)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single dose of azithromycin (for patients)
Number of subjects: 0
Study: 8581842

Group type: EXPERIMENTAL
Intervention: Local nasal immunotherapy (LNIT) with allergen in powder form
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 2523787

Group type: EXPERIMENTAL
Intervention: Metformin (0.5 g x 3 daily)
Number of subjects: 10
Study: 795700

Group type: EXPERIMENTAL
Intervention: Verapamil (0.1 mg/kg i.v.)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (5 mg, sublingual)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Propranolol (0.1 mg/kg i.v.)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Dipyridamol (20 mg i.v.)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo (20 ml saline i.v.)
Number of subjects: 5
Study: 31472812

Group type: EXPERIMENTAL
Intervention: Nurse-run, physician-supervised AF clinic
Number of subjects: 413

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 413
Study: 28267470

Group type: EXPERIMENTAL
Intervention: Community health worker-based program (CHW arm)
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Usual care (Control arm)
Number of subjects: 1200
Study: 25924844

Group type: EXPERIMENTAL
Intervention: E'Sevo-3%
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: E'Sevo-4%
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: E'Sevo-5%
Number of subjects: 61
Study: 24113028

Group type: EXPERIMENTAL
Intervention: Daily oral 100 mg enteric-coated aspirin
Number of subjects: 19383

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 19383
Study: 21437676

Group type: EXPERIMENTAL
Intervention: Operational multidisciplinary antibiotic team
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group (no operational team)
Number of subjects: 17
Study: 19722768

Group type: EXPERIMENTAL
Intervention: Water birth delivery (experimental group)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Conventional delivery method (control group)
Number of subjects: 106
Study: 17822526

Group type: EXPERIMENTAL
Intervention: Behavioral intervention to reduce smoking, depression, and intimate partner violence during pregnancy
Number of subjects: 1070

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1070

Group type: EXPERIMENTAL
Intervention: Behavioral intervention
Number of subjects: 1070
Study: 15026104

Group type: EXPERIMENTAL
Intervention: Up-front incentive (25 dollars gift card) with the first survey mailing
Number of subjects: 2100

Group type: COMPARATOR
Intervention: Promised incentive (25 dollars gift card) on receipt of completed survey
Number of subjects: 2100

Group type: EXPERIMENTAL
Intervention: Obstetrician-gynecologists (up-front incentive)
Number of subjects: 2100

Group type: EXPERIMENTAL
Intervention: Pediatricians (up-front incentive)
Number of subjects: 2100
Study: 11490106

Group type: EXPERIMENTAL
Intervention: Cerebral amyloid angiopathy (CAA)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Hypertension (HTN)
Number of subjects: 83
Study: 9164907

Group type: EXPERIMENTAL
Intervention: Transaxillary muscle-sparing closure of patent ductus arteriosus
Number of subjects: 10
Study: 1772296

Group type: EXPERIMENTAL
Intervention: misoprostol (400 micrograms)
Number of subjects: 25

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 25
Study: 11541691

Group type: EXPERIMENTAL
Intervention: Transdermal scopolamine (TAS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Promethazine and ephedrine (P/E)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Scopolamine and dextroamphetamine (S/D)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intramuscularly administered promethazine
Number of subjects: 0
Study: 31967515

Group type: EXPERIMENTAL
Intervention: Fentanyl
Number of subjects: 125

Group type: COMPARATOR
Intervention: Control group (Remifentanil)
Number of subjects: 125
Study: 31284424

Group type: EXPERIMENTAL
Intervention: Partly fermented infant formula with 30% fermented formula and 0.8 g/100 mL scGOS/lcFOS
Number of subjects: 200

Group type: COMPARATOR
Intervention: Non-fermented control infant formula without scGOS/lcFOS
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Partly fermented infant formula with prebiotics
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Both study formulae
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Partly fermented formula with prebiotics
Number of subjects: 200
Study: 28893433

Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC) - 3 cycles of 5-min inflation (300mmHg) and deflation on the left arm
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control - deflated cuff placement
Number of subjects: 72
Study: 26153177

Group type: EXPERIMENTAL
Intervention: Educational session about caring for patients with indwelling urinary catheters
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no educational session)
Number of subjects: 0
Study: 24766987

Group type: EXPERIMENTAL
Intervention: Exercise-based cardiac rehabilitation program (aerobic exercise at 70% to 85% of maximal heart rate for 3 sessions per week plus usual care)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Usual care (Control Group)
Number of subjects: 96
Study: 23079125

Group type: EXPERIMENTAL
Intervention: MTX 7.5‐20 mg/week + cyclosporine (CYA) 2.5‐4 mg/kg (combination)
Number of subjects: 160

Group type: COMPARATOR
Intervention: MTX + placebo-CYA (monotherapy)
Number of subjects: 160
Study: 20659915

Group type: EXPERIMENTAL
Intervention: Dexamethasone 0.5 mg kg(‐1) (maximum 10 mg)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 77
Study: 18796506

Group type: EXPERIMENTAL
Intervention: Home-based Chronic Disease Self-Management Program
Number of subjects: 415

Group type: COMPARATOR
Intervention: Usual care control
Number of subjects: 415
Study: 16251562

Group type: EXPERIMENTAL
Intervention: 10 mg of 0.2% hypobaric tetracaine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 12 mg of 0.2% hypobaric tetracaine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 14 mg of 0.2% hypobaric tetracaine
Number of subjects: 60
Study: 12087923

Group type: EXPERIMENTAL
Intervention: 30 mg of nifedipine in the test preparation 'XL' (Nifecard)
Number of subjects: 42

Group type: COMPARATOR
Intervention: 30 mg of nifedipine in the reference formulation 'LA'
Number of subjects: 42
Study: 10334239

Group type: EXPERIMENTAL
Intervention: Age groups (20-39, 40-59, 60-79, 80-100)
Number of subjects: 40
Study: 8761190

Group type: EXPERIMENTAL
Intervention: Corticosteroid injections
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo injections
Number of subjects: 10
Study: 1416009

Group type: EXPERIMENTAL
Intervention: Sprotte 24 G needle (n = 28)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Vygon 29 G needle (n = 28)
Number of subjects: 56

Group type: COMPARATOR
Intervention: General anaesthesia (n = 28)
Number of subjects: 56